AML/CFT Program Requirements Proposed Rule - Joint Consultation

Three federal banking regulators (FDIC, OCC, NCUA) jointly published a proposed rule to modernize AML/CFT program requirements for supervised banks and credit unions. The amendments would align agency regulations with the Anti-Money Laundering Act of 2020 and FinCEN requirements, including risk-based program design, explicit customer due diligence integration, and a new FinCEN consultation framework. The proposal requires comments within 60 days of Federal Register publication.

Operation Prince: Inside a $15 billion crypto fraud takedown

ACAMS Today published an analysis of Operation Prince, a major law enforcement action targeting a cryptocurrency fraud scheme estimated at $15 billion. The article, authored by Ari Redbord, examines the fraud mechanics, regulatory response, and implications for compliance professionals in the digital asset space.

Threat finance: Cryptocurrencies, covert funds and advanced detection

ACAMS published a member perspective article by Dr. Robert Pakla on threat finance trends involving cryptocurrencies and covert fund detection methods. The article discusses emerging patterns in illicit finance and advanced detection technologies for identifying suspicious cryptocurrency transactions.

2026 U.S. Risk Assessments Redefine Financial Crime and National Security Priorities

ACAMS published an analysis on March 13, 2026 examining how the 2026 U.S. risk assessments are reshaping financial crime and national security priorities for compliance professionals and financial institutions. The article discusses emerging trends in anti-money laundering enforcement and strategic priorities that institutions should monitor.

Agentic workflows for financial crime

ACAMS published a member perspective article examining how agentic AI workflows can be applied to financial crime compliance. The article discusses practical implementation approaches for using autonomous AI agents in transaction monitoring, fraud detection, and suspicious activity reporting. The piece targets compliance professionals and financial crime specialists seeking to understand emerging applications of artificial intelligence in anti-money laundering operations.

Global Shift Toward Outcomes-Based Anti-Financial Crime Frameworks

ACAMS published an analysis examining the global trend toward outcomes-based approaches in anti-financial crime (AFC) compliance frameworks. The piece discusses how regulators and financial institutions are shifting from traditional activity-based compliance toward measuring actual outcomes and effectiveness. This analysis is directed at compliance professionals and AML specialists within financial institutions.

BOL-148 substance abuse treatment method patent grant to Ceruvia Lifesciences

The USPTO granted patent US12594272B2 to Ceruvia Lifesciences LLC covering a method of treating substance abuse using 2-bromo-lysergic acid diethylamide (BOL-148). The patent contains 6 claims and was filed on March 25, 2021, with Carey Turnbull listed as the inventor.

Rhamnolipid compositions with antibiotics, UNC Chapel Hill patent

The USPTO granted patent US12594289B2 to The University of North Carolina at Chapel Hill on April 7, 2026, covering compositions combining biosurfactants (rhamnolipids) with antibiotics to enhance antibacterial potency against infections. The patent includes 18 claims and names Brian Conlon, Sarah Conlon, and Lauren Radlinski as inventors.

Prevention of tolerance to stimulant ADHD medication

USPTO granted patent US12594250B2 to James Martin Swanson for methods of preventing accumulated tolerance to stimulant medication used in ADHD treatment. The patent discloses pharmaceutical compositions with controlled-release formulations combining immediate-release and sustained-release components to counteract acute tolerance. The patent contains 16 claims covering methods of treatment using ascending delivery profiles.

Hydroflumethiazide composition for treating TNF-α-related diseases

USPTO granted Patent US12594279B2 to SK Chemicals Co., Ltd. for a composition containing hydroflumethiazide as an active ingredient for preventing or treating TNF-α-related diseases. The patent covers formulations effective at inhibiting TNF-α expression, demonstrating superior efficacy compared to methotrexate and hydroxychloroquine for rheumatoid arthritis treatment. The patent includes 8 claims and covers CPC classifications related to pharmaceutical compositions.